Welcome to our dedicated page for 89Bio news (Ticker: ETNB), a resource for investors and traders seeking the latest updates and insights on 89Bio stock.
News for 89bio, Inc. (ETNB) centers on its role as a clinical-stage biopharmaceutical company developing therapies for liver and cardiometabolic diseases, as well as its corporate transition following its acquisition by Roche. Company press releases and SEC reports highlight pegozafermin, a fibroblast growth factor 21 (FGF21) analog engineered with glycoPEGylated technology, as its lead product candidate in Phase 3 development for metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis and severe hypertriglyceridemia (SHTG).
Visitors to this ETNB news page can review historical announcements about 89bio’s clinical programs, including updates on the ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in MASH and the ENTRUST Phase 3 trial in SHTG. Releases describe trial designs, planned topline data timing, and the company’s expectations regarding potential regulatory pathways, as well as operational items such as construction of a commercial-scale production facility for pegozafermin.
The news flow also covers corporate and capital markets activity. This includes inducement stock option grants under Nasdaq Listing Rule 5635(c)(4), participation in major healthcare and biopharma investor conferences, and quarterly financial updates that discuss research and development spending and general and administrative expenses in the context of advancing the Phase 3 programs.
A key development in the ETNB news record is the announcement of an Agreement and Plan of Merger with Roche Holdings, Inc., followed by the commencement and completion of a tender offer. Related communications describe the cash consideration, the structure of non-tradeable contingent value rights (CVRs) tied to pegozafermin milestones, and the subsequent delisting of ETNB from The Nasdaq Global Market as 89bio became a wholly owned subsidiary of Roche. Investors and researchers can use this page as an archive of 89bio’s historical news, from clinical milestones to the closing of the Roche transaction.
89bio (NASDAQ: ETNB) has announced a definitive agreement to be acquired by Roche in a deal valued at up to $3.5 billion. Shareholders will receive $14.50 per share in cash at closing, representing a 79% premium to the last trading price, plus a non-tradeable CVR worth up to $6.00 per share tied to specific milestones.
The CVR payments include $2.00 for first commercial sale in F4 MASH cirrhotic patients, $1.50 for achieving $3.0 billion in annual global sales, and $2.50 for reaching $4.0 billion in annual global sales. The transaction, unanimously approved by 89bio's Board, is expected to close in Q4 2025, subject to customary conditions including regulatory approval and tender of majority shares.
89bio (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on liver and cardiometabolic disease therapies, announced the approval of inducement grants for three new employees. The Compensation Committee approved non-qualified stock options to purchase 64,750 shares of common stock on September 1, 2025.
The grants, made under the company's 2023 Inducement Plan, will vest over four years, with 25% vesting after one year and the remainder vesting in 12 quarterly installments. The exercise price equals the closing price of 89bio's stock on the grant date. These grants comply with Nasdaq Listing Rule 5635(c)(4) and serve as employment inducements.
89bio (Nasdaq: ETNB), a clinical-stage biopharmaceutical company developing therapies for liver and cardiometabolic diseases, has announced its participation in three upcoming investor conferences in September 2025.
Management will participate in fireside chats at Citi's 2025 Biopharma Back to School Conference on September 3 at 11:15 AM EDT and the Cantor Global Healthcare Conference on September 4 at 11:30 AM EDT. The company will also conduct one-on-one meetings at the H.C. Wainwright Global Investment Conference on September 8. Webcasts will be available on 89bio's investor website with 30-day replay access.
89bio (NASDAQ: ETNB) reported Q2 2025 financial results and provided updates on its clinical programs. The company maintains a strong financial position with $561.2 million in cash and equivalents. Key clinical milestones include expected topline data from the Phase 3 ENTRUST trial for severe hypertriglyceridemia in Q1 2026, and Phase 3 ENLIGHTEN trials data for MASH treatment in 1H 2027 and 2028.
The company reported a net loss of $111.5 million for Q2 2025, with R&D expenses of $103.9 million, including a $42.4 million payment for a commercial-scale production facility. G&A expenses increased to $11.9 million, primarily due to higher personnel costs.
The ENLIGHTEN trials are designed to support accelerated approval for pegozafermin in both non-cirrhotic and cirrhotic MASH patients, with FDA and EMA alignment.
89bio (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focusing on liver and cardiometabolic disease therapies, has announced inducement grants for three new employees. The Compensation Committee approved non-qualified stock options to purchase 267,000 shares of common stock on August 1, 2025.
The grants, made under the company's 2023 Inducement Plan, will vest over four years, with 25% vesting after one year and the remainder vesting in 12 quarterly installments. The exercise price equals the closing price of 89bio's stock on the grant date. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
[]89bio (Nasdaq: ETNB), a clinical-stage biopharmaceutical company specializing in liver and cardiometabolic disease therapies, announced inducement grants for two new employees. The Compensation Committee approved non-qualified stock options to purchase 32,350 shares of common stock on July 2, 2025.
The grants, made under the company's 2023 Inducement Plan, will vest over four years, with 25% vesting after one year and the remainder vesting in 12 quarterly installments. The exercise price equals the closing price of 89bio's stock on the grant date.
89bio (Nasdaq: ETNB) has announced the approval of inducement grants for seven new employees by its Board's Compensation Committee. The grants consist of non-qualified stock options to purchase 183,885 shares of common stock, issued on May 6, 2025. These grants, made under the company's 2023 Inducement Plan, follow Nasdaq Listing Rule 5635(c)(4) and serve as employment incentives. The options' exercise price equals ETNB's closing price on the grant date and will vest over four years - 25% after one year and the remaining in 12 quarterly installments, contingent on continued employment.
89bio (NASDAQ: ETNB), a clinical-stage biopharmaceutical company specializing in liver and cardiometabolic disease therapies, has announced its management team's participation in two major healthcare investor conferences in May 2025:
1. BofA Securities 2025 Health Care Conference - Fireside chat scheduled for Wednesday, May 14, 2025, at 1:40 PM ET
2. 2025 RBC Capital Markets Global Healthcare Conference - Fireside chat scheduled for Tuesday, May 20, 2025, at 9:30 AM ET
Both presentations will be available via webcast on 89bio's investor relations website, with replays accessible for approximately 30 days after each event.
FAQ
What is the current stock price of 89Bio (ETNB)?
What is the market cap of 89Bio (ETNB)?
